New triple therapy aims to shrink stomach tumors before surgery

NCT ID NCT06766578

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people with locally advanced stomach or gastroesophageal junction cancer. Before surgery, patients receive low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX). The goal is to see if this combination can completely eliminate the tumor before surgery. About 32 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shandong Provincial Hospital

    RECRUITING

    Jinan, Shandong, 250021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••